WP
REGN icon

Woodline Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Woodline Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.3M Buy
67,751
+2,783
+4% +$2.13M 0.2% 130
2025
Q4 		$50.1M Buy
64,968
+4,004
+7% +$2.72M 0.19% 128
2025
Q3 		$34.3M Buy
60,964
+2,186
+4% +$1.24M 0.16% 174
2025
Q2 		$30.9M Sell
58,778
-47,439
-45% -$26.5M 0.16% 185
2025
Q1 		$67.4M Buy
106,217
+2,938
+3% +$2.02M 0.44% 40
2024
Q4 		$73.6M Buy
103,279
+3,862
+4% +$3.24M 0.5% 35
2024
Q3 		$105M Sell
99,417
-82,480
-45% -$91.8M 0.88% 14
2024
Q2 		$191M Buy
181,897
+11,295
+7% +$10.9M 1.82% 2
2024
Q1 		$164M Buy
170,602
+512
+0.3% +$487K 1.51% 3
2023
Q4 		$149M Buy
170,090
+33,518
+25% +$27.6M 1.62% 3
2023
Q3 		$112M Buy
136,572
+88,910
+187% +$69.9M 1.32% 7
2023
Q2 		$34.2M Sell
47,662
-106,659
-69% -$82.2M 0.41% 61
2023
Q1 		$127M Sell
154,321
-5,172
-3% -$3.9M 1.73% 3
2022
Q4 		$115M Sell
159,493
-27,864
-15% -$20.6M 1.54% 5
2022
Q3 		$129M Buy
187,357
+134,565
+255% +$84.7M 1.8% 4
2022
Q2 		$31.2M Sell
52,792
-52,702
-50% -$34.3M 0.48% 48
2022
Q1 		$73.7M Buy
105,494
+15,248
+17% +$9.65M 1.2% 8
2021
Q4 		$57M Buy
90,246
+14,400
+19% +$8.85M 0.82% 26
2021
Q3 		$45.9M Sell
75,846
-2,013
-3% -$1.25M 0.75% 26
2021
Q2 		$43.5M Sell
77,859
-108,040
-58% -$54.7M 0.81% 27
2021
Q1 		$88M Buy
185,899
+165,695
+820% +$80.7M 1.95% 5
2020
Q4 		$9.76M Buy
+20,204
New +$10.9M 0.26% 117
2020
Q3 		– Sell
-30,722
Closed -$19.2M – 214
2020
Q2 		$19.2M Buy
30,722
+3,245
+12% +$1.84M 0.76% 48
2020
Q1 		$13.4M Buy
+27,477
New +$11.3M 0.96% 33

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Woodline Partners's REGN Position: Q1 2026 in Review

Woodline Partners increased its Regeneron Pharmaceuticals (REGN) stake by 4.3% in Q1 2026, buying an estimated $2.13M and bringing the position to 67,751 shares worth $52.3M. The position accounts for 0.2% of the portfolio, ranked #130.

Woodline Partners first reported a position in REGN in Q1 2020 and has held it in 24 quarters since. The position peaked at $191M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Woodline Partners held 67,751 shares of Regeneron Pharmaceuticals worth $52.3M as of Q1 2026.
  • Woodline Partners bought 2,783 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.13M.
  • Regeneron Pharmaceuticals made up 0.2% of Woodline Partners's portfolio in Q1 2026, its #130 holding.
  • Woodline Partners first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 24 quarters since.
  • Woodline Partners's Regeneron Pharmaceuticals position peaked at $191M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.